NCT07299409
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07299409
Title First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Nathalie Levasseur
Indications
Therapies
Age Groups: adult | senior
Covered Countries CAN


No variant requirements are available.